Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Published Date: 13 Sep 2024

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

Read Full News

Latest News

Definium's LSD-based Anxiety, Depression Drug Scores Another Trial Win

Definium Therapeutics said on Monday its LSD-based treatment reduced symptoms of generalized anxiety disorder ⁠in a second successful late-stage study for the...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

‘Modest’ Differences in OAT Should Not Obscure Benefits

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Alzheimer's Blood Test Gets FDA Clearance

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Todays Updates

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Antibiotic use in patients under hospice care is associated with an increased risk for mortality; for infectious hospice-qualifying conditions, antibiotic use is linked to extended survival.

Todays Updates

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Antibiotic use in patients under hospice care is associated with an increased risk for mortality; for infectious hospice-qualifying conditions, antibiotic use is linked to extended survival.

Latest News

Definium Therapeutics said on Monday its LSD-based treatment reduced symptoms of generalized anxiety disorder ⁠in a second successful late-stage study for the...

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

(This Aug 27 story has been republished, with no changes to text.)

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

News All Time

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

FDA Approves First CELMoD Drug for Multiple Myeloma

Iberdomide indicated as part of combination regimen for relapsed or refractory disease

Study Questions How Prostate Cancer Focal Therapy Is Being Used

Half of procedures occurred in settings not supported by guidelines

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

Health news and commentary gathered by MedPage Today staff

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

News, features, and commentary about cancer-related issues

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Testing could give doctors an early start on life-preserving cancer treatments

SBRT Misses the Mark in Prostate Cancer Trial

No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years

What Caused This Young Man's Bladder Cancer

Occupational exposure, family history make tempting hypotheses

Dramatic Increase in Active Surveillance Use for Prostate Cancer

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

Clinicians faced with presumed dermatologic AEs urged to consider all differentials

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

News, features, and commentary about cancer-related issues

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

Preschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.

US Mental Health Treatment Rates Rise But Gaps Persist

Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.

Recommended News For You

Smarter targeted radiotherapy just as effective for low-risk breast cancer and reduces risk of side effects

AI is useful in low-resource areas for triaging breast masses.

ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Team finds broken 'brake' on cancer mutation machine.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

Study suggests radiation therapy benefits misjudged when clinical factors alone guide breast cancer treatment

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Recommended Articles For You

Guidelines for Transfusion Threshold Assessment 

Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions 

Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far 

Pediatric Bone-Marrow Niche Development: Mechanisms, Clinical Relevance, and Emerging Insights 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

2.

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

3.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

4.

Scientists develop scans that light up aggressive cancer tumors for better treatment

5.

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

1.

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options

2.

Molecular Interaction Maps in Refractory Blood Disease: Mechanistic Insights and Clinical Applications

3.

All About Ferric Gluconate – The Best Source Of Iron For Anemia

4.

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice

5.

Spatially Targeted Intratumoral Therapeutics: Mechanisms, Clinical Applications, and Future Directions

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

3.

Recognizing the Signs of Anemia in Adults

4.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

5.

Clinical Insights in Oncology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot